Table 2 Distribution of the 70 EPEC isolates from different clinical outcomes analysed in this study.

From: Genomic diversity of EPEC associated with clinical presentations of differing severity

Phylogroup or lineage* Total isolates (% of total) BFP Clinical outcomes (% of phylogroup or lineage) Location (% of phylogroup or lineage)
    LI NSI AI The Gambia Mali Mozambique Kenya Pakistan
Total isolates 70 61 (87.1) 24 (34.2) 23 (32.9) 23 (32.9) 18 (25.7) 3 (4.3) 22 (31.4) 21 (30) 6 (8.6)
Phylogroup B2 39 (55.7) 38 (62.3) 13 (33.3) 12 (30.8) 14 (35.9) 6 (15.4) 2 (5.1) 17 (43.6) 12 (30.8) 2 (5.1)
 EPEC1 8 (11.4) 8 (100) 4 (50) 1 (12.5) 3 (37.5) 2 (25) 0 (0) 2 (25) 4 (50) 0 (0)
 EPEC4 8 (11.4) 7 (87.5) 2 (25) 4 (50) 2 (25) 2 (25) 1 (12.5) 3 (37.5) 2 (25) 0 (0)
 EPEC8 10 (14.3) 10 (100) 5 (50) 4 (40) 1 (10) 2 (20) 0 (0) 4 (40) 4 (40) 0 (0)
 EPEC9 6 (8.6) 6 (100) 2 (33.3) 2 (33.3) 2 (33.3) 0 (0) 0 (0) 5 (83.3) 0 (0) 1 (16.7)
 uAEEC 7 (10) 7 (100) 0 (0) 1 (14.3) 6 (85.7) 0 (0) 1 (14.3) 3 (42.8) 2 (28.6) 1 (14.3)
Phylogroup B1 24 (34.3) 20 (32.8) 10 (41.7) 8 (33.3) 6 (25) 7 (29.2) 1 (4.2) 5 (20.8) 7 (29.2) 4 (16.6)
 EPEC2 8 (11.4) 8 (100) 3 (37.5) 4 (50) 1 (12.5) 1 (12.5) 0 (0) 1 (12.5) 2 (25) 4 (50)
 EPEC7 11 (15.7) 9 (81.8) 6 (54.5) 3 (27.3) 2 (18.2) 2 (18.2) 1 (9.1) 3 (27.3) 5 (45.4) 0 (0)
 uAEEC 5 (7.1) 3 (60) 1 (20) 1 (20) 3 (60) 4 (80) 0 (0) 1 (20) 0 (0) 0 (0)
Phylogroup A 5 (7.1) 3 (4.9) 1 (20) 3 (60) 1 (20) 3 (60) 0 (0) 0 (0) 2 (40) 0 (0)
 EPEC5 3 (4.3) 2 (66.7) 1 (33.3) 1 (33.3) 1 (33.3) 1 (33.3) 0 (0) 0 (0) 2 (66.7) 0 (0)
 EPEC10 2 (2.9) 1 (50) 0 (0) 2 (100) 0 (0) 2 (100) 0 (0) 0 (0) 0 (0) 0 (0)
Phylogroup E 2 (2.9) 0 (0) 0 (0) 0 (0) 2 (100) 2 (100) 0 (0) 0 (0) 0 (0) 0 (0)
 uAEEC 2 (2.9) 0 (0) 0 (0) 0 (0) 2 (100) 2 (100) 0 (0) 0 (0) 0 (0) 0 (0)
Phylogroups B1, B2, E uAEEC Total 14 (20) 10 (71.4) 1 (7.1) 2 (14.3) 11 (78.6) 6 (42.9) 1 (7.1) 4 (28.6) 2 (14.3) 1 (7.1)
  1. *The phylogenomic lineages are determined based on the genome phylogeny, and uAEEC indicates an ‘uncharacterized’ AEEC that is not in a known lineage;
  2. includes isolates that have a truncated BFP operon; the percentages are calculated for each lineage;
  3. the clinical outcomes are lethal (LI), non-lethal symptomatic (NSI) and asymptomatic (AI).